Predictions of the ADMET properties of candidate drug molecules utilizing different QSAR/QSPR modelling approaches

Current Drug Metabolism

Volumn 11, Issue 4, 2010, Pages 285-295

  Khan, Mahmud Tareq Hassan ^a  

^a Center for Biosafety   (Norway)

Author keywords

ADMET; Artificial neural network; Drugability; Inductive logic programming; logD; logP; Machine learning; Molecular descriptor; Multiple linear regressions; PSA; QSAR modeling; Support vector machine

Indexed keywords

LEAD; PROTEIN; PROTEOME; RNA;

BINDING AFFINITY; BLOOD BRAIN BARRIER; CHEMICAL STRUCTURE; COMPUTER MODEL; COMPUTER PREDICTION; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG METABOLISM; DRUG TOXICITY; MATHEMATICAL ANALYSIS; PHYSICAL CHEMISTRY; PROTEIN BINDING; PROTEIN TARGETING; QUANTITATIVE STRUCTURE ACTIVITY RELATION; QUANTITATIVE STRUCTURE PROPERTY RELATION; REVIEW; STRUCTURE ACTIVITY RELATION;

DRUG DESIGN; HUMANS; MODELS, MOLECULAR; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; TISSUE DISTRIBUTION;

EID: 77953314142     PISSN: 13892002     EISSN: None     Source Type: Journal    
DOI: 10.2174/138920010791514306     Document Type: Review

References (176)

1. Khan, M. T.; Sylte, I. Predictive QSAR modeling for the successful predictions of the ADMET properties of candidate drug molecules. Curr. Drug Discov. Technol., 2007, 4(3), 141-149
2. Yamashita, F.; Hashida, M. In silico approaches for predicting ADME properties of drugs. Drug Metab. Pharmacokinet., 2004, 19(5), 327-338
3. DiMasi, J. A.; Hansen, R. W.; Grabowski, H. G. The price of innovation: new estimates of drug development costs. J. Health Econ., 2003, 22(2), 151-185
4. Tsaioun, K.; Bottlaender, M.; Mabondzo, A. ADDME - Avoiding Drug Development Mistakes Early: central nervous system drug discovery perspective. BMC Neurol., 2009, 9(Suppl 1), S1.
5. Gonzalez-Diaz, H.; Prado-Prado, F.; Ubeira, F. M. Predicting antimicrobial drugs and targets with the MARCH-INSIDE approach. Curr. Top. Med. Chem., 2008, 8(18), 1676-1690
6. Gonzalez-Diaz, H. Quantitative studies on Structure-Activity and Structure-Property Relationships (QSAR/QSPR). Curr. Top. Med. Chem., 2008, 8(18), 1554.
7. Cruz-Monteagudo, M.; González-Díaz, H.; Borges, F.; Dominguez, E. R.; Cordeiro, M. N. 3D-MEDNEs: an alternative "in Silico" technique for chemical research in toxicology. 2. Quantitative Proteome-toxicity relationships (QPTR) based on mass spectrum spiral entropy. Chem. Res. Toxicol., 2008, 2(1), 619-632.
8. González-Díaz, H.; Vilar, S.; Santana, L.; Uriarte, E. Medicinal chemistry and bioinformatics - current trends in drugs discovery with networks topological indices. Curr. Top. Med. Chem., 2007, 7(10), 1025-1039
9. González-Díaz, H.; Marrero, Y.; Hernandez, I.; Bastida, I.; Tenorio, E.; Nasco, O.; Uriarte, E.; Castanedo, N.; Cabrera, M. A.; Aguila, E.; Marrero, O.; Morales, A.; Perez, M.3D-MEDNEs: an alternative "in silico" technique for chemical research in toxicology. 1. prediction of chemically induced agranulocytosis. Chem. Res. Toxicol., 2003, 16(10), 1318-1327
10. Cruz-Monteagudo, M.; González-Díaz, H. Unified drug-target interaction thermodynamic Markov model using stochastic entropies to predict multiple drugs side effects. Eur. J. Med. Chem., 2005, 40(10), 1030-1041 (Pubitemid 41421108)
11. Cruz-Monteagudo, M.; González-Díaz, H.; Agüero-Chapin, G.; Santana, L.; Borges, F.; Domínguez, R. E.; Podda, G.; Uriarte, E. Computational chemistry development of a unified free energy markov model for the distribution of 1300 chemicals to 38 different environmental or biological systems. J. Comput. Chem., 2007, 28, 1909-1922.
12. Blake, J. F. Chemoinformatics - predicting the physicochemical properties of 'drug-like' molecules. Curr. Opin. Biotechnol., 2000, 11(1), 104-107
13. Vistoli, G.; Pedretti, A.; Testa, B. Assessing drug-likeness - what are we missing? Drug Discov. Today, 2008, 13(7-8), 285-294
14. Groom, C. R.; Hopkins, A. L. Protein kinase drugs - optimism doesn't wait on facts. Drug Discov. Today, 2002, 7(15), 801-802
15. Hopkins, A. L.; Groom, C. R. The druggable genome. Nat. Rev. Drug Discov., 2002, 1(9), 727-730
16. Lipinski, C.; Hopkins, A. Navigating chemical space for biology and medicine. Nature, 2004, 432(7019), 855-861
17. Kubinyi, H. Drug research: myths, hype and reality. Nat. Rev. Drug Discov., 2003, 2(8), 665-668 (Pubitemid 37368830)
18. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev., 2001, 46(1-3), 3-26.
19. Lipinski, C. A. Drug-like properties and the causes of poor solubility and poor permeability. J. Pharmacol. Toxicol. Methods, 2000, 44(1), 235-249
20. Rodriguez-Soca, Y.; Munteanu, C. R.; Prado-Prado, F. J.; Dorado, J.; Pazos Sierra, A.; Gonzalez-Diaz, H. Trypano-PPI: a web server for prediction of unique targets in trypanosome proteome by using electrostatic parameters of protein-protein interactions. J. Proteome Res., 2009, doi:10.1021/pr900827b.
21. Pérez-Montoto, L. G.; Prado-Prado, F.; Ubeira, F. M.; González-Díaz, H. Study of parasitic infections, cancer, and other diseases with mass-spectrometry and quantitative proteome-disease relationships. Curr. Proteomics, 2009, 6, 246-261.
22. Munteanu, C. R.; Vazquez, J. M.; Dorado, J.; Sierra, A. P.; Sanchez-Gonzalez, A.; Prado-Prado, F. J.; Gonzalez-Diaz, H. Complex network spectral moments for ATCUN motif DNA cleavage: first predictive study on proteins of human pathogen parasites. J. Proteome Res., 2009, 8(11), 5219-5228.
23. Munteanu, C. R.; Magalhaes, A. L.; Uriarte, E.; Gonzalez-Diaz, H. Multi-target QPDR classification model for human breast and colon cancer-related proteins using star graph topological indices. J. Theor. Biol., 2009, 257(2), 303-311
24. González-Díaz, H.; Prado-Prado, F.; Pérez-Montoto, L. G.; Duardo-Sánchez, A.; López-Díaz, A. QSAR models for proteins of parasitic organisms, plants and human guests: theory, applications, legal protection, taxes, and regulatory issues. Curr. Proteomics, 2009, 6, 214-227.
25. Concu, R.; Dea-Ayuela, M. A.; Perez-Montoto, L. G.; Bolas-Fernandez, F.; Prado-Prado, F. J.; Podda, G.; Uriarte, E.; Ubeira, F. M.; Gonzalez-Diaz, H. Prediction of enzyme classes from 3D structure: a general model and examples of experimental-theoretic scoring of peptide mass fingerprints of Leishmania proteins. J. Proteome Res., 2009, 8(9), 4372-4382
26. Aguero-Chapin, G.; Varona-Santos, J.; de la Riva, G. A.; Antunes, A.; Gonzalez-Villa, T.; Uriarte, E.; Gonzalez-Diaz, H. Alignment-free prediction of polygalacturonases with pseudofolding topological indices: experimental isolation from coffea arabica and prediction of a new sequence. J. Proteome Res., 2009, 8(4), 2122-2128.
27. González-Díaz, H.; González-Díaz, Y.; Santana, L.; Ubeira, F. M.; Uriarte, E. Proteomics, networks and connectivity indices. Proteomics, 2008, 8, 750-778.
28. González-Díaz, H.; Saiz-Urra, L.; Molina, R.; Santana, L.; Uriarte, E. A model for the recognition of protein kinases based on the entropy of 3D van der waals interactions. J. Proteome Res., 2007, 6(2), 904-908.
29. Lill, M. A. Multi-dimensional QSAR in drug discovery. Drug Discov. Today, 2007, 12(23-24), 1013-1017
30. Marshall, G. R.; Cramer, R. D., 3rd. Three-dimensional structure-activity relationships. Trends Pharmacol. Sci., 1988, 9(8), 285-289
31. Hopfinger, A. J.; Wang, S.; Tokarski, J. S.; Jin, B.; Albuquerque, M.; Madhav, P. J.; Duraiswami, C. Construction of 3D-QSAR models using the 4D-QSAR analysis formalism. J. Am. Chem. Soc., 1997, 119(43), 10509-10524.
32. Ekins, S.; Bravi, G.; Binkley, S.; Gillespie, J. S.; Ring, B. J.; Wikel, J. H.; Wrighton, S. A. Three- and four-dimensional-quantitative structure activity relationship (3D/4D-QSAR) analyses of CYP2C9 inhibitors. Drug Metab. Dispos., 2000, 28(8), 994-1002.
33. Vedani, A.; Briem, H.; Dobler, M.; Dollinger, H.; McMasters, D. R. Multiple-conformation and protonation-state representation in 4D-QSAR: the neurokinin-1 receptor system. J. Med. Chem., 2000, 43(23), 4416-4427
34. Lukacova, V.; Balaz, S. Multimode ligand binding in receptor site modeling: implementation in CoMFA. J. Chem. Inf. Comput. Sci., 2003, 43(6), 2093-2105
35. Overton, C. E. Studien über die Narkose, Gustav Fischer Verlag: Jena, Germany 1901.
36. Hansch, C.; Steward, A. R. The use of substituent constants in the analysis of the structure - activity relationship in penicillin derivatives. J. Med. Chem., 1964, 7, 691-694
37. Free, S. M., Jr.; Wilson, J. W. A Mathematical Contribution to Structure-Activity Studies. J. Med. Chem., 1964, 7, 395-399
38. Vedani, A.; Dobler, M.5D-QSAR: the key for simulating induced fit? J. Med. Chem., 2002, 45(11), 2139-2149
39. Lill, M. A.; Vedani, A.; Dobler, M. Raptor: combining dual-shell representation, induced-fit simulation, and hydrophobicity scoring in receptor modeling: application toward the simulation of structurally diverse ligand sets. J. Med. Chem., 2004, 47(25), 6174-6186
40. Lill, M. A.; Dobler, M.; Vedani, A. Prediction of small-molecule binding to cytochrome P450 3A4: flexible docking combined with multidimensional QSAR. Chem. Med. Chem., 2006, 1(1), 73-81.
41. Vedani, A.; Dobler, M.; Lill, M. A. Combining protein modeling and 6D-QSAR. Simulating the binding of structurally diverse ligands to the estrogen receptor. J. Med. Chem., 2005, 48(11), 3700-3703
42. Todeschini, R.; Consonni, V. Handbook of Molecular Descriptors. Methods and Principles in Medicinal Chemistry. Mannhold, R.; Kubinyi, H. and Timmerman, H., Eds., 2000, 11, 368-371.
43. Todeschini, R.; Consonni, V. Handbook of Molecular Descriptors, Wiley-VCH 2000.
44. Gibbs, A. C.; Agrafiotis, D. K. In Exploiting Chemical Diversity for Drug Discovery, Barlett, P.A.; Entzeroth, M.; Eds.; RSC Publishing: Cambridge, 2006, pp. 137-159.
45. Hou, T. J.; Xu, X. J. ADME evaluation in drug discovery. 3. Modeling blood-brain barrier partitioning using simple molecular descriptors. J. Chem. Inf. Comput. Sci., 2003, 43(6), 2137-2152
46. Brown, R. D.; Martin, Y. C. Use of structure-activity data to compare structure-based clustering methods and descriptors for use in compound selection. J. Chem. Inf. Model., 1996, 36(3), 572-584.
47. Cramer, R. D.; Bunce, J. D. Pharmacochemistry Library 1987, 10, 3-12.
48. Livingstone, D. J. The characterization of chemical structures using molecular properties. a survey. J. Chem. Inf. Model., 2000, 40(2), 195-209.
49. Weiss, G. A. Exploring the Milky Way of molecular diversity Combinatorial chemistry and molecular diversity. Curr. Opin. Chem. Biol., 2007, 11(3), 241-243.
50. Johnson, M. A.; Maggiora, G. N. Concepts and Applications of Molecular Similarities, Wiley: New York 1990.
51. Willett, P. similarity and clustering in chemical information systems. Wiley: New York 1987.
52. Willett, P.; Barnard, J. M.; Downs, G. M. Chemical similarity searching. J. Chem. inf. Model., 1998, 38(6), 983-996.
53. Agrafiotis, D. K.; Lobanov, V. S.; Rassokhin, D. N.; Izrailev, S. In Virtual Screening for Bioactive Molecules, Bohm, H.-J.; Schneider, G.; Eds.; Wiley: Weinheim, 2000, pp. 265-300.
54. Hou, T.; Wang, J.; Zhang, W.; Wang, W.; Xu, X. Recent advances in computational prediction of drug absorption and permeability in drug discovery. Curr. Med. Chem., 2006, 13(22), 2653-2667.
55. Narayanan, R.; Gunturi, S. B. In silico ADME modelling: prediction models for blood-brain barrier permeation using a systematic variable selection method. Bioorg. Med. Chem., 2005, 13(8), 3017-3128.
56. Mitic, L. L.; Anderson, J. M. Molecular architecture of tight junctions. Annu. Rev. Physiol., 1998, 60, 121-142.
57. Hoffman, B.; Cho, S. J.; Zheng, W.; Wyrick, S.; Nichols, D. E.; Mailman, R. B.; Tropsha, A. Quantitative structure-activity relationship modeling of dopamine D(1) antagonists using comparative molecular field analysis, genetic algorithms-partial least-squares, and K nearest neighbor methods. J. Med. Chem., 1999, 42(17), 3217-3226.
58. de Julian-Ortiz, J. V.; Garcia-Domenech, R.; Galvez, J.; Pogliani, L. Predictability and prediction of lowest observed adverse effect levels in a structurally heterogeneous set of chemicals. SAR QSAR Environ. Res., 2005, 16(3), 263-272.
59. Marrero-Ponce, Y.; Meneses-Marcel, A.; Castillo-Garit, J. A.; Machado-Tugores, Y.; Escario, J. A.; Barrio, A. G.; Pereira, D. M.; Nogal-Ruiz, J. J.; Aran, V. J.; Martinez-Fernandez, A. R.; Torrens, F.; Rotondo, R.; Ibarra-Velarde, F.; Alvarado, Y. J. Predicting antitrichomonal activity: a computational screening using atom-based bilinear indices and experimental proofs. Bioorg. Med. Chem., 2006, 14(19), 6502-6524.
60. Murcia-Soler, M.; Perez-Gimenez, F.; Garcia-March, F. J.; Salabert-Salvador, M. T.; Diaz-Villanueva, W.; Medina-Casamayor, P. Discrimination and selection of new potential antibacterial compounds using simple topological descriptors. J. Mol. Graph Model, 2003, 21(5), 375-390
61. Prado-Prado, F. J.; Gonzalez-Diaz, H.; de la Vega, O. M.; Ubeira, F. M.; Chou, K. C. Unified QSAR approach to antimicrobials. Part 3: first multi-tasking QSAR model for input-coded prediction, structural back-projection, and complex networks clustering of antiprotozoal compounds. Bioorg. Med. Chem., 2008, 16(11), 5871-5880
62. Prado-Prado, F. J.; Gonzalez-Diaz, H.; Santana, L.; Uriarte, E. Unified QSAR approach to antimicrobials. Part 2: predicting activity against more than 90 different species in order to halt antibacterial resistance. Bioorg. Med. Chem., 2007, 15(2), 897-902.
63. Hirst, J. D.; King, R. D.; Sternberg, M. J. Quantitative structure-activity relationships by neural networks and inductive logic programming. II. The inhibition of dihydrofolate reductase by triazines. J. Comput. Aided Mol. Des., 1994, 8(4), 421-432
64. Hirst, J. D.; King, R. D.; Sternberg, M. J. Quantitative structure-activity relationships by neural networks and inductive logic programming. I. The inhibition of dihydrofolate reductase by pyrimidines. J. Comput. Aided Mol. Des., 1994, 8(4), 405-420.
65. King, R. D.; Muggleton, S.; Lewis, R. A.; Sternberg, M. J. Drug design by machine learning: the use of inductive logic programming to model the structure-activity relationships of trimethoprim analogues binding to dihydrofolate reductase. Proc. Natl. Acad. Sci. USA, 1992, 89(23), 11322-11326.
66. Jensen, B. F.; Vind, C.; Padkjaer, S. B.; Brockhoff, P. B.; Refsgaard, H. H. In silico prediction of cytochrome P450 2D6 and 3A4 inhibition using Gaussian kernel weighted k-nearest neighbor and extended connectivity fingerprints, including structural fragment analysis of inhibitors versus noninhibitors. J. Med. Chem., 2007, 50(3), 501-511
67. Zheng, W.; Tropsha, A. Novel variable selection quantitative structure - property relationship approach based on the k-nearestneighbor principle. J. Chem. Inf. Comput. Sci., 2000, 40(1), 185-194.
68. Yuan, H.; Wang, Y.; Cheng, Y. Local and global quantitative structure-activity relationship modeling and prediction for the baseline toxicity. J. Chem. Inf. Model, 2007, 47(1), 159-169.
69. Ajmani, S.; Jadhav, K.; Kulkarni, S. A. Three-dimensional QSAR using the k-nearest neighbor method and its interpretation. J. Chem. Inf. Model, 2006, 46(1), 24-31.
70. Hoshi, K.; Kawakami, J.; Kumagai, M.; Kasahara, S.; Nishimura, N.; Nakamura, H.; Sato, K. An analysis of thyroid function diagnosis using Bayesian-type and SOM-type neural networks. Chem. Pharm. Bull (Tokyo), 2005, 53(12), 1570-1574.
71. Fernandez, M.; Caballero, J. Bayesian-regularized genetic neural networks applied to the modeling of non-peptide antagonists for the human luteinizing hormone-releasing hormone receptor. J. Mol. Graph Model, 2006, 25(4), 410-422.
72. Fernandez, M.; Caballero, J.; Tundidor-Camba, A. Linear and nonlinear QSAR study of N-hydroxy-2-[(phenylsulfonyl) amino]acetamide derivatives as matrix metalloproteinase inhibitors. Bioorg. Med. Chem., 2006, 14(12), 4137-4150.
73. Ghasemi, J.; Saaidpour, S. Quantitative structure-property relationship study of n-octanol-water partition coefficients of some of diverse drugs using multiple linear regression. Anal. Chim. Acta., 2007, 604(2), 99-106.
74. Ghasemi, J.; Saaidpour, S. QSPR prediction of aqueous solubility of drug-like organic compounds. Chem. Pharm. Bull (Tokyo), 2007, 55(4), 669-674.
75. O'Connor, K. M.; Corrigan, O. I. Comparison of the physicochemical properties of the N-(2-hydroxyethyl) pyrrolidine, diethylamine and sodium salt forms of diclofenac. Int. J. Pharm., 2001, 222(2), 281-293.
76. Huuskonen, J. Estimation of aqueous solubility in drug design. Comb. Chem. High Throughput Screen, 2001, 4(3), 311-316. (Pubitemid 32433642)
77. Huuskonen, J. Estimation of water solubility from atom-type electrotopological state indices. Environ. Toxicol. Chem., 2001, 20(3), 491-497. (Pubitemid 32861530)
78. Livingstone, D. J.; Ford, M. G.; Huuskonen, J. J.; Salt, D. W. Simultaneous prediction of aqueous solubility and octanol/water partition coefficient based on descriptors derived from molecular structure. J. Comput. Aided Mol. Des., 2001, 15(8), 741-752.
79. Catana, C.; Gao, H.; Orrenius, C.; Stouten, P. F. Linear and nonlinear methods in modeling the aqueous solubility of organic compounds. J. Chem. Inf. Model, 2005, 45(1), 170-176.
80. Hansch, C.; Quinlan, J. E.; Lawrence, G. L. The linear free energy relationship between partition coefficients and the aqueoussolubility of organic liquids. J. Org. Chem., 1968, 33, 347-350.
81. Lien, E. J.; Lien, L. L.; Gao, H. In QSAR and Molecular Modeling: Concept, Computational tools and Biologic Applications, Sanz, F.; Giraldo, J.; Manaut, F.; Eds.; Prous Science Publishers: Barcelona, 1995, pp. 94-100.
82. Yalkowsky, S. H.; Valvani, S. C. Solubility and partitioning I: Solubility of nonelectrolytes in water. J. Pharm. Sci., 1980, 69(8), 912-922
83. Ran, Y.; Jain, N.; Yalkowsky, S. H. Prediction of aqueous solubility of organic compounds by the general solubility equation (GSE). J. Chem. Inf. Comput. Sci., 2001, 41(5), 1208-1217
84. Ran, Y.; Yalkowsky, S. H. Prediction of drug solubility by the general solubility equation (GSE). J. Chem. Inf. Comput. Sci., 2001, 41(2), 354-357
85. Jain, N.; Yalkowsky, S. H. Estimation of the aqueous solubility I: application to organic nonelectrolytes. J. Pharm. Sci., 2001, 90(2), 234-352.
86. Klopman, G.; Wang, S.; Balthasar, D. M. Estimation of aqueous solubility of organic molecules by the group contribution approach. Application to the study of biodegradation. J. Chem. Inf. Comput. Sci., 1992, 32(5), 474-482.
87. Huuskonen, J. Estimation of aqueous solubility for a diverse set of organic compounds based on molecular topology. J. Chem. Inf. Comput. Sci., 2000, 40(3), 773-777.
88. Huuskonen, J.; Rantanen, J.; Livingstone, D. Prediction of aqueous solubility for a diverse set of organic compounds based on atom-type electrotopological state indices. Eur. J. Med. Chem., 2000, 35(12), 1081-1088.
89. Huuskonen, J. J.; Livingstone, D. J.; Tetko, I. I. Neural network modeling for estimation of partition coefficient based on atom-type electrotopological state indices. J. Chem. Inf. Comput. Sci., 2000, 40(4), 947-955
90. Bodor, N.; Huang, M. J. A new method for the estimation of the aqueous solubility of organic compounds. J. Pharm. Sci., 1992, 81(9), 954-960
91. Bodor, N.; Huang, M. J. An extended version of a novel method for the estimation of partition coefficients. J. Pharm. Sci., 1992, 81(3), 272-281
92. Yalkowsky, S. H. Estimation of the aqueous solubility of complex organic compounds. Chemosphere, 1993, 26, 1239-1261.
93. Jain, N.; Yalkowsky, S. H. Estimation of the Aqueous Solubility I: Application to Organic Non-Electrolytes. J. Pharm. Sci., 2000, 90, 234-252.
94. Huuskonen, J.; Salo, M.; Taskinen, J. Aqueous solubility prediction of drugs based on molecular topology and neural network modeling. J. Chem. Inf. Comput. Sci., 1998, 38(3), 450-456 (Pubitemid 128594458)
95. McElroy, N. R.; Jurs, P. C. Prediction of aqueous solubility of heteroatom-containing organic compounds from molecular structure. J. Chem. Inf. Comput. Sci., 2001, 41(5), 1237-1247
96. McFarland, J. W.; Avdeef, A.; Berger, C. M.; Raevsky, O. A. Estimating the water solubilities of crystalline compounds from their chemical structures alone. J. Chem. Inf. Comput. Sci., 2001, 41(5), 1355-1359
97. Liu, R.; So, S. S. Development of quantitative structure-property relationship models for early ADME evaluation in drug discovery. 1. Aqueous solubility. J. Chem. Inf. Comput. Sci., 2001, 41(6), 1633-1639
98. Tetko, I. V.; Tanchuk, V. Y.; Kasheva, T. N.; Villa, A. E. Estimation of aqueous solubility of chemical compounds using E-state indices. J. Chem. Inf. Comput. Sci., 2001, 41(6), 1488-1493
99. Tetko, I. V.; Tanchuk, V. Y.; Kasheva, T. N.; Villa, A. E. Internet software for the calculation of the lipophilicity and aqueous solubility of chemical compounds. J. Chem. Inf. Comput. Sci., 2001, 41(2), 246-252
100. Engkvist, O.; Wrede, P. High-throughput, in silico prediction of aqueous solubility based on one- and two-dimensional descriptors. J. Chem. Inf. Comput. Sci., 2002, 42(5), 1247-1249
101. Yan, A.; Gasteiger, J. Prediction of aqueous solubility of organic compounds based on a 3D structure representation. J. Chem. Inf. Comput. Sci., 2003, 43(2), 429-434
102. Butina, D.; Gola, J. M. Modeling aqueous solubility. J. Chem. Inf. Comput. Sci., 2003, 43(3), 837-841
103. Wegner, J. K.; Zell, A. Prediction of aqueous solubility and partition coefficient optimized by a genetic algorithm based descriptor selection method. J. Chem. Inf. Comput Sci., 2003, 43(3), 1077-1084
104. Nirmalakhandan, N. N. P.; Speece, R. E. Prediction of aqueous solubility of organic chemicals based on molecular structure. 2. Application to PNAs, PCBs, PCDDs, et. Environ. Sci. Technol., 1989, 23, 708-713.
105. Suzuki, T. Development of an automatic estimation system for both the partition coefficient and aqueous solubility. J. Comput. Aided Mol. Des., 1991, 5(2), 149-166
106. Kuhne, R.; Ebert, R. U.; Kleint, F.; Schmidt, G.; Schuurmann, G. Group contribution method to estimate water solubility of organic chemicals. Chemosphere 1995, 30, 2061-2077. (Pubitemid 26435718)
107. Lee, Y.; Myrdal, P. B.; Yalkowsky, S. H. Aqueous functional group activity coefficients (AQUAFAC) 4: Application to complex organic compounds. Chemosphere, 1996, 33, 2129-2144.
108. Klopman, G.; Zhu, H. Estimation of the aqueous solubility of organic molecules by the group contribution approach. J. Chem. Inf. Comput. Sci., 2001, 41(2), 439-445
109. Hou, T. J.; Xia, K.; Zhang, W.; Xu, X. J. ADME evaluation in drug discovery. 4. Prediction of aqueous solubility based on atom contribution approach. J. Chem. Inf. Comput. Sci., 2004, 44(1), 266-275
110. Gao, H.; Shanmugasundaram, V.; Lee, P. Estimation of aqueous solubility of organic compounds with QSPR approach. Pharm. Res., 2002, 19(4), 497-503.
111. Garg, P.; Verma, J. In silico prediction of blood brain barrier permeability: an Artificial Neural Network model. J. Chem. Inf. Model, 2006, 46(1), 289-297
112. Liu, X.; Tu, M.; Kelly, R. S.; Chen, C.; Smith, B. J. Development of a computational approach to predict blood-brain barrier permeability. Drug Metab. Dispos., 2004, 32(1), 132-139
113. Zhao, Y. H.; Abraham, M. H.; Ibrahim, A.; Fish, P. V.; Cole, S.; Lewis, M. L.; Groot, M. J.; Reynolds, D. P. Predicting Penetration Across the Blood-Brain Barrier from Simple Descriptors and Fragmentation Schemes. J. Chem. Inf. Model, 2007, 47(1), 170-175.
114. Abbott Joan, N. Prediction of blood-brain barrier permeation in drug discovery from in vivo, in vitro and in silico models. . Drug Discov. Today: Technol., 2004, 1, 407-416.
115. Reichel, A.; Begley, D. J.; Abbott, N. J. An overview of in vitro techniques for blood-brain barrier studies. Methods Mol. Med., 2003, 89, 307-324
116. Young, R. C.; Mitchell, R. C.; Brown, T. H.; Ganellin, C. R.; Griffiths, R.; Jones, M.; Rana, K. K.; Saunders, D.; Smith, I. R.; Sore, N. E.; et al. Development of a new physicochemical model for brain penetration and its application to the design of centrally acting H2 receptor histamine antagonists. J. Med. Chem., 1988, 31(3), 656-671
117. Lombardo, F.; Blake, J. F.; Curatolo, W. J. Computation of brain-blood partitioning of organic solutes via free energy calculations. J. Med. Chem., 1996, 39(24), 4750-4755
118. Abraham, M. H.; Takacs-Novak, K.; Mitchell, R. C. On the partition of ampholytes: application to blood-brain distribution. J. Pharm. Sci., 1997, 86(3), 310-315
119. Norinder, U.; Sjoberg, P.; Osterberg, T. Theoretical calculation and prediction of brain-blood partitioning of organic solutes using MolSurf parametrization and PLS statistics. J. Pharm. Sci., 1998, 87(8), 952-959
120. Clark, D. E. Rapid calculation of polar molecular surface area and its application to the prediction of transport phenomena. 2. Prediction of blood-brain barrier penetration. J. Pharm. Sci., 1999, 88(8), 815-821
121. Kelder, J.; Grootenhuis, P. D.; Bayada, D. M.; Delbressine, L. P.; Ploemen, J. P. Polar molecular surface as a dominating determinant for oral absorption and brain penetration of drugs. Pharm. Res., 1999, 16(10), 1514-1519
122. Crivori, P.; Cruciani, G.; Carrupt, P. A.; Testa, B. Predicting blood-brain barrier permeation from three-dimensional molecular structure. J. Med. Chem., 2000, 43(11), 2204-2216
123. Ertl, P.; Rohde, B.; Selzer, P. Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties. J. Med. Chem., 2000, 43(20), 3714-3717
124. Keseru, G. M.; Molnar, L. High-throughput prediction of blood-brain partitioning: a thermodynamic approach. J. Chem. Inf. Comput. Sci., 2001, 41(1), 120-128
125. Liu, R.; Sun, H.; So, S. S. Development of quantitative structure-property relationship models for early ADME evaluation in drug discovery. 2. Blood-brain barrier penetration. J. Chem. Inf. Comput. Sci., 2001, 41(6), 1623-1632
126. Rose, K.; Hall, L. H.; Kier, L. B. Modeling blood-brain barrier partitioning using the electrotopological state. J. Chem. Inf. Comput. Sci., 2002, 42(3), 651-666
127. Hou, T.; Xu, X. ADME evaluation in drug discovery. 1. Applications of genetic algorithms to the prediction of blood-brain partitioning of a large set of drugs. J. Mol. Model, 2002, 8(12), 337-349
128. Hutter, M. C. Prediction of blood-brain barrier permeation using quantum chemically derived information. J. Comput. Aided Mol. Des., 2003, 17(7), 415-433
129. Abraham, M. H. The factors that influence permeation across the blood-brain barrier. Eur. J. Med. Chem., 2004, 39(3), 235-240
130. González-Díaz, H.; Cabrera-Pérez, M. A.; Agüero-Chapín, G.; Cruz-Monteagudo, M.; Castañedo-Cancio, N.; del Río, M. A.; Uriarte, E. Multi-target QSPR assemble of a Complex Network for the distribution of chemicals to biphasic systems and biological tissues. Chemomet. Intelligent Lab. Syst., 2008, 94, 160-165.
131. Lombardo, F.; Gifford, E.; Shalaeva, M. Y. In silico ADME prediction: data, models, facts and myths. Mini. Rev. Med. Chem., 2003, 3(8), 861-875
132. van de Waterbeemd, H.; Gifford, E. ADMET in silico modelling: towards prediction paradise? Nat. Rev. Drug Discov., 2003, 2(3), 192-204.
133. Hall, L. M.; Hall, L. H.; Kier, L. B. Modeling drug albumin binding affinity with e-state topological structure representation. J. Chem. Inf. Comput. Sci., 2003, 43(6), 2120-2128
134. Hall, L. M.; Hall, L. H.; Kier, L. B. QSAR modeling of beta-lactam binding to human serum proteins. J. Comput. Aided Mol. Des., 2003, 17(2-4), 103-118
135. Soskić, M.; Magnus, V. Binding of ring-substituted indole-3-acetic acids to human serum albumin. Bioorg. Med. Chem. , 2007, 15(13), 4595-4600
136. Caballero, J.; Zampini, F. M.; Collina, S.; Fernández, M. Quantitative structure-activity relationship modeling of growth hormone secretagogues agonist activity of some tetrahydroisoquinoline 1-carboxamides. Chem. Biol. Drug Des., 2007, 69(1), 48-55.
137. Sakurai, A.; Kurata, A.; Onishi, Y.; Hirano, H.; Ishikawa, T. Prediction of drug-induced intrahepatic cholestasis: in vitro screening and QSAR analysis of drugs inhibiting the human bile salt export pump. Expert Opin. Drug Saf., 2007, 6(1), 71-86.
138. Chohan, K. K.; Paine, S. W.; Waters, N. J. Quantitative structure activity relationships in drug metabolism. Curr. Top. Med. Chem., 2006, 6(15), 1569-1578
139. Srinivas, E.; Murthy, J. N.; Rao, A. R.; Sastry, G. N. Recent advances in molecular modeling and medicinal chemistry aspects of phospho-glycoprotein. Curr. Drug Metab., 2006, 7(2), 205-217
140. Yang, G. F.; Huang, X. Development of quantitative structure-activity relationships and its application in rational drug design. Curr. Pharm. Des., 2006, 12(35), 4601-4611
141. Arimoto, R. Computational models for predicting interactions with cytochrome p450 enzyme. Curr. Top. Med. Chem., 2006, 6(15), 1609-1618
142. Allen, D. D.; Geldenhuys, W. J. Molecular modeling of blood-brain barrier nutrient transporters: in silico basis for evaluation of potential drug delivery to the central nervous system. Life Sci., 2006, 78(10), 1029-1033
143. Cronin, M. T.; Walker, J. D.; Jaworska, J. S.; Comber, M. H.; Watts, C. D.; Worth, A. P. Use of QSARs in international decision-making frameworks to predict ecologic effects and environmental fate of chemical substances. Environ. Health Perspect., 2003, 111(10), 1376-1390 (Pubitemid 37021143)
144. Ekins, S.; Wrighton, S. A. Application of in silico approaches to predicting drug - drug interactions. J. Pharmacol. Toxicol. Methods, 2001, 45(1), 65-69
145. Gao, H.; Hansch, C. QSAR of P450 oxidation: on the value of comparing kcat and km with kcat/km. Drug Metab. Rev., 1996, 28(4), 513-526 (Pubitemid 26417561)
146. Hansch, C.; Mekapati, S. B.; Kurup, A.; Verma, R. P. QSAR of cytochrome P450. Drug Metab. Rev., 2004, 36(1), 105-156
147. Kulkarni, S. A.; Zhu, J.; Blechinger, S. In silico techniques for the study and prediction of xenobiotic metabolism: a review. Xenobiotica, 2005, 35(10-11), 955-973
148. Lewis, D. F. Structural models for cytochrome P450-mediated catalysis. Scientific. World J., 2003, 3, 536-545
149. Lewis, D. F.; Modi, S.; Dickins, M. Quantitative structure-activity relationships (QSARs) within substrates of human cytochromes P450 involved in drug metabolism. Drug Metab. Drug Interact., 2001, 18(3-4), 221-242 (Pubitemid 34038463)
150. Li, Y.; Harte, W. E. A review of molecular modeling approaches to pharmacophore models and structure-activity relationships of ion channel modulators in CNS. Curr. Pharm. Des., 2002, 8(2), 99-110.
151. Locuson, C. W.; Wahlstrom, J. L. Three-dimensional quantitative structure-activity relationship analysis of cytochromes p450: effect of incorporating higher-affinity ligands and potential new applications. Drug Metab. Dispos., 2005, 33(7), 873-878
152. Mekenyan, O. G.; Dimitrov, S. D.; Pavlov, T. S.; Veith, G. D. A systematic approach to simulating metabolism in computational toxicology. I. The TIMES heuristic modelling framework. Curr. Pharm. Des., 2004, 10(11), 1273-1293
153. Rettie, A. E.; Jones, J. P. Clinical and toxicological relevance of CYP2C9: drug-drug interactions and pharmacogenetics. Annu. Rev. Pharmacol. Toxicol., 2005, 45, 477-494
154. Siraki, A. G.; Chevaldina, T.; Moridani, M. Y.; O'Brien, P. J. Quantitative structure-toxicity relationships by accelerated cytotoxicity mechanism screening. Curr. Opin. Drug Discov. Dev., 2004, 7(1), 118-125
155. Soffers, A. E.; Boersma, M. G.; Vaes, W. H.; Vervoort, J.; Tyrakowska, B.; Hermens, J. L.; Rietjens, I. M. Computer-modeling-based QSARs for analyzing experimental data on biotransformation and toxicity. Toxicol. In Vitro, 2001, 15(4-5), 539-551
156. van de Waterbeemd, H. High-throughput and in silico techniques in drug metabolism and pharmacokinetics. Curr. Opin. Drug Discov. Dev., 2002, 5(1), 33-43.
157. Verma, R. P. Understanding topoisomerase I and II in terms of QSAR. Bioorg. Med. Chem., 2005, 13(4), 1059-1067
158. Wang, R. B.; Kuo, C. L.; Lien, L. L.; Lien, E. J. Structure-activity relationship: analyses of p-glycoprotein substrates and inhibitors. J. Clin. Pharm. Ther., 2003, 28(3), 203-228
159. Smith, P. A.; Sorich, M. J.; Low, L. S.; McKinnon, R. A.; Miners, J. O. Towards integrated ADME prediction: past, present and future directions for modelling metabolism by UDP-glucuronosyl-transferases. J. Mol. Graph. Model, 2004, 22(6), 507-517
160. Hansch, C.; Leo, A.; Mekapati, S. B.; Kurup, A. QSAR and ADME. Bioorg. Med. Chem., 2004, 12(12), 3391-3400
161. Cheng, D.; Xu, W. R.; Liu, C. X. Relationship of quantitative structure and pharmacokinetics in fluoroquinolone antibacterials. World J. Gastroenterol., 2007, 13(17), 2496-2503 (Pubitemid 46929507)
162. Gieleciak, R.; Polanski, J. Modeling robust QSAR. 2. iterative variable elimination schemes for CoMSA: application for modeling benzoic acid pKa values. J. Chem. Inf. Model., 2007, 47(2), 547-556 (Pubitemid 46615956)
163. Valerio, L. G., Jr. In silico toxicology for the pharmaceutical sciences. Toxicol. Appl. Pharmacol., 2009, 241(3), 356-370
164. Yang, C.; Valerio, L. G., Jr.; Arvidson, K. B. Computational toxicology approaches at the US Food and Drug Administration. Altern. Lab. Anim., 2009, 37(5), 523-531
165. Casanola-Martin, G. M.; Khan, M. T.; Marrero-Ponce, Y.; Ather, A.; Sultankhodzhaev, M. N.; Torrens, F. New tyrosinase inhibitors selected by atomic linear indices-based classification models. Bioorg. Med. Chem. Lett., 2006, 16(2), 324-330
166. Casanola-Martin, G. M.; Marrero-Ponce, Y.; Khan, M. T.; Ather, A.; Khan, K. M.; Torrens, F.; Rotondo, R. Dragon method for finding novel tyrosinase inhibitors: Biosilico identification and experimental in vitro assays. Eur. J. Med. Chem., 2007, 42(11-12), 1370-1381
167. Casanola-Martin, G. M.; Marrero-Ponce, Y.; Khan, M. T.; Ather, A.; Sultan, S.; Torrens, F.; Rotondo, R. TOMOCOMD-CARDD descriptors-based virtual screening of tyrosinase inhibitors: evaluation of different classification model combinations using bond-based linear indices. Bioorg. Med. Chem., 2007, 15(3), 1483-1503
168. Marrero-Ponce, Y.; Khan, M. T.; Casanola Martin, G. M.; Ather, A.; Sultankhodzhaev, M. N.; Torrens, F.; Rotondo, R. Prediction of tyrosinase inhibition activity using atom-based bilinear indices. Chem. Med. Chem., 2007, 2(4), 449-478
169. Marrero-Ponce, Y.; Khan, M. T.; Casanola-Martin, G. M.; Ather, A.; Sultankhodzhaev, M. N.; Garcia-Domenech, R.; Torrens, F.; Rotondo, R. Bond-based 2D TOMOCOMD-CARDD approach for drug discovery: aiding decision-making in 'in silico' selection of new lead tyrosinase inhibitors. J. Comput. Aided. Mol. Des., 2007, 21(4), 167-188
170. Buchwald, P.; Bodor, N. Computer-aided drug design: the role of quantitative structure-property, structure-activity and structure-metabolism relationships (QSPR, QSAR, QSMR). Drugs Future, 2002, 27, 577-588.
171. Hou, T.; Wang, J.; Zhang, W.; Xu, X. ADME Evaluation in Drug Discovery. 7. Prediction of Oral Absorption by Correlation and Classification. J. Chem. Inf. Model, 2007, 47(1), 208-218
172. Hou, T.; Xu, X. Recent development and application of virtual screening in drug discovery: an overview. Curr. Pharm. Des., 2004, 10(9), 1011-1033
173. Hou, T. J.; Xu, X. J. ADME evaluation in drug discovery. 2. Prediction of partition coefficient by atom-additive approach based on atom-weighted solvent accessible surface areas. J. Chem. Inf. Comput. Sci., 2003, 43(3), 1058-1067
174. Hou, T. J.; Zhang, W.; Xia, K.; Qiao, X. B.; Xu, X. J. ADME evaluation in drug discovery. 5. Correlation of Caco-2 permeation with simple molecular properties. J Chem. Inf. Comput. Sci., 2004, 44(5), 1585-1600
175. Kolossov, E.; Stanforth, R. The quality of QSAR models: problems and solutions. SAR QSAR Environ. Res., 2007, 18(1-2), 89-100.
176. Wang, J.; Skolnik, S. Recent advances in physicochemical and ADMET profiling in drug discovery. Chem. Biodivers, 2009, 6(11), 1887-1899